Inhibitors of Mitochondrial Fission

Abstract

Pharmaceutical compositions that include inhibitors of mitochondrial fission are described for the treatment and/or mitigation of cancer, pulmonary arterial hypertension, cardioprotection, stroke, coronary heart disease, neurological disorder, a neurodegenerative disease, Parksinonism, Huntington's Chorea, Alzheimer's disease, diabetic cardiomyopathy, fatty liver diseases, non-alcoholic fatty liver diseases, or alcohol-related liver disease.

1 . A pharmaceutical composition comprising Compound 6 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle: 
       
         
           
           
               
               
           
         
       
     
     
         2 . The pharmaceutical composition of  claim 1 , for the treatment and/or mitigation of one or more of cancer, pulmonary arterial hypertension, cardioprotection, stroke, coronary heart disease, a neurodegenerative disease, Parksinonism, Huntington's Chorea, Alzheimer's disease, diabetic cardiomyopathy, fatty liver diseases, non-alcoholic fatty liver diseases, and alcohol-related liver disease. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutically acceptable vehicle is an excipient. 
     
     
         4 . The pharmaceutical composition of  claim 2 , wherein the cancer is metastatic cancer. 
     
     
         5 . The pharmaceutical composition of  claim 4 , wherein the metastatic cancer is breast cancer, ovarian cancer, lung cancer, pancreatic cancer, melanoma, colorectal cancer, kidney cancer, cervical cancer, testicular cancer, or liver cancer. 
     
     
         6 . The pharmaceutical composition of  claim 1 , further comprising one or more antineoplastic agent(s). 
     
     
         7 . (canceled) 
     
     
         8 . A method for reducing or inhibiting mitochondrial fission, comprising administering to a subject in need thereof an effective amount of the pharmaceutical composition of  claim 1 . 
     
     
         9 . (canceled) 
     
     
         10 . The method of  claim 8 , wherein the mitochondrial fission is associated with one or more of cancer, pulmonary arterial hypertension, cardioprotection, stroke, coronary heart disease, a neurodegenerative disease, Parksinonism, Huntington's Chorea, Alzheimer's disease, diabetic cardiomyopathy, fatty liver diseases, non-alcoholic fatty liver diseases, and alcohol-related liver disease. 
     
     
         11 . (canceled) 
     
     
         12 . The method of  claim 10 , wherein the cancer is metastatic cancer. 
     
     
         13 . The method of  claim 12 , wherein the metastatic cancer is breast cancer, ovarian cancer, lung cancer, pancreatic cancer, melanoma, colorectal cancer, kidney cancer, cervical cancer, testicular cancer, or liver cancer. 
     
     
         14 .- 17 . (canceled) 
     
     
         18 . The pharmaceutical composition of  claim 1 , wherein the compound of  claim 1  is present in an amount from 1 to 1000 mg. 
     
     
         19 . The method of  claim 8 , wherein an effective amount is an amount from 1 to 1000 mg. 
     
     
         20 . The method of  claim 8 , wherein an effective amount is an amount from 5 to 500 mg.